m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT03138
 [1]
Histone modification H3K18la EP300 YTHDF3 Direct Enhancement m6A modification PRDX3 PRDX3 YTHDF3 : m6A sites
m6A Modification:
m6A Regulator YTH domain-containing family protein 3 (YTHDF3) READER
 Regulator Info 
m6A Target Thioredoxin-dependent peroxide reductase, mitochondrial (PRDX3)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Histone modification (HistMod)
Epigenetic Regulator Histone acetyltransferase p300 (P300) WRITER View Details
Regulated Target Histone H3 lysine 18 lactylation (H3K18la) View Details
Downstream Gene YTHDF3 View Details
Crosstalk Relationship Histone modification  →  m6A Enhancement
Crosstalk Mechanism histone modification directly impacts m6A modification through modulating the level of m6A regulator
Crosstalk Summary p300 is responsible for catalyzing the H3K18ac modification. Histone H3 lysine 18 lactylation (H3K18la)-regulated YTHDF3 is involved in SEV-induced microglial pyroptosis. YTHDF3 stabilizes Thioredoxin-dependent peroxide reductase, mitochondrial (PRDX3) mRNA through m6A modification. H3K18la regulates YTHDF3/PRDX3 mediated pyroptosis to mitigating SEV-induced cognitive dysfunction in neonatal mice.
Responsed Disease Cognitive impairment ICD-11: MB21
 Disease Info 
In-vitro Model
 BV-2 Normal Mus musculus CVCL_0182
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Histone acetyltransferase p300 (P300) 2 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name CCS1477 Phase 1/2 [2]
Synonyms
CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 134457551
TTD: DIY4C2
 Compound Name FT-7051 Phase 1 [3]
MOA Inhibitor
External Link
TTD: DT8IL6
References
Ref 1 Histone lactylation protects against sevoflurane-induced cognitive impairment by regulating YTHDF3/PRDX3 mediated microglial pyroptosis in neonatal mice. Int Immunopharmacol. 2025 Apr 4;151:114269. doi: 10.1016/j.intimp.2025.114269. Epub 2025 Feb 28.
Ref 2 Targeting the p300/CBP Axis in Lethal Prostate Cancer. Cancer Discov. 2021 May;11(5):1118-1137. doi: 10.1158/2159-8290.CD-20-0751. Epub 2021 Jan 11.
Ref 3 Clinical pipeline report, company report or official report of FORMA Therapeutics.